TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Immunovia AB ( (SE:IMMNOV) ) is now available.
Immunovia has announced that the Centers for Medicare & Medicaid Services (CMS) finalized a national payment rate of $897 for its PancreaSure test, effective January 1, 2026. This milestone is crucial in Immunovia’s reimbursement strategy, allowing the company to begin billing insurance providers. The company is now focused on obtaining a Local Coverage Determination (LCD) by submitting clinical data to demonstrate the test’s validity and utility, aiming for completion in 2026.
More about Immunovia AB
Immunovia AB is a diagnostic company focused on increasing survival rates for pancreatic cancer patients through early detection. The company develops and commercializes tests to detect proteins and blood-based antibodies indicative of pancreatic cancer, collaborating with healthcare providers, experts, and advocacy groups to reach high-risk individuals. The USA is the largest market for pancreatic cancer detection, with an estimated 1.8 million high-risk individuals who could benefit from annual surveillance testing.
Average Trading Volume: 8,879,457
Technical Sentiment Signal: Sell
Current Market Cap: SEK164.2M
For a thorough assessment of IMMNOV stock, go to TipRanks’ Stock Analysis page.